Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Revance Therapeutics, Inc.

< Previous 1 2 Next >
Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Announces Proposed Public Offering of Common Stock
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Provides Corporate Update at Investor Day
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Host Investor Day on September 19, 2023
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
Revance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
From Revance Therapeutics, Inc.
Via Business Wire
Tickers RVNC
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.